While additional research is required to investigate the cut-off values of CCL28 and betacellulin in a more extensive population, and the assessment of lymphocyte count in the tumor immune microenvironment (TME) was not conducted in this study, it has provided the impetus for further exploration into the underlying processes of combination therapy. This evidence concerns the gene BTC and neoplasm.